Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 11/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235579 | 0.89 | MMP13 (0.34) | TBXAS1MMP13 | |
| SCHEMBL6231683 | 0.84 | PTGS2 (0.37) | — | |
| SCHEMBL6250624 | 0.80 | MMP13 (0.38) | MMP13 | |
| SCHEMBL6265127 | 0.79 | KDM4E (0.43) | MMP13 | |
| SCHEMBL6632613 | 0.75 | KDM4E (0.38) | TBXAS1NLRP3GAAMMP13 | |
| SCHEMBL6232596 | 0.71 | MMP13 (0.46) | NLRP3GAAMMP13 | |
| SCHEMBL6229954 | 0.70 | MMP13 (0.47) | NLRP3GAAMMP13 | |
| SCHEMBL6252956 | 0.69 | MMP13 (0.49) | TBXAS1GAAMMP13 | |
| SCHEMBL11067952 | 0.68 | TBXAS1 (0.67) | TBXAS1GAAMKNK1MKNK2 | |
| SCHEMBL7039135 | 0.68 | MMP13 (0.54) | GAAMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | claimed |
| EP-1534274-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1525030-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6849648-B2 | Phenylene alkyne matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1434585-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040023969-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-05 | — | — | US | disclosed |
| US-20040019055-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004007025-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006914-A1 | COMBINATION OF AN ALLOSTERIC ALKYNE INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2003-07-31 | — | — | US | disclosed |
| WO-2003032999-A1 | ALKYNE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019055-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TBXAS1 2198/4885NLRP3 1746/4885GAA 1503/4885 |
| US-20040023969-A1 | Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TBXAS1 3369/4885NLRP3 2847/4885GAA 1207/4885 |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | TBXAS1 2457/4885NLRP3 1830/4885GAA 714/4885 |
| US-20030144274-A1 | Alkyne matrix metalloproteinase inhibitors | MMP11, MMP13, MMP3 | TBXAS1 540/4885NLRP3 3481/4885GAA 397/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | TBXAS1 2383/4885NLRP3 1230/4885GAA 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.